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Although  prophylactic  cranial  irradiation  (PCI)  has  been  the  standard  of  practice  for patients  success-
fully  treated  for  limited  stage  small  cell  lung  cancer  for decades,  subsequent  changes  in  patient  selection,ccepted 20 April 2015
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updated  brain  imaging  guidelines,  an increased  understanding  of the  mechanisms  underlying  the dele-
terious  effects  of whole  brain  irradiation  as  well  as ongoing  investigations  into  improving  radiation
treatment  delivery  have  begun  to question  the  current  role  of  PCI.  Who  should  be  treated  and  how?
This  review  attempts  to gather  together  evidence  for  improving  patient  selection  and  describe  potential
improvements  in  treatment  delivery.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
The original rationale for prophylactic cranial irradiation (PCI)
s advocated by Hansen [1] in 1973 is that CNS relapse in small
ell lung cancer is analogous to isolated CNS relapse in acute lym-
hoblastic leukaemia (ALL). Now most patients with ALL can expect
o celebrate becoming a cancer survivor ﬁve years later typically
ithout PCI. The outlook for patients diagnosed with small cell lung
ancer, most of whom do undergo PCI, remains far more guarded
ith only ∼6–7% of patients alive 5 years following their diagnosis
2]. Nevertheless, PCI had become the standard of care for many
atients treated for small cell lung cancer before the ﬁrst meta-
nalysis supporting its use was published in 1999 [3] particularly in
atients with limited stage disease achieving a complete response.
CI halves the rate of intracranial relapse (especially if it is to be the
rst site of relapse) from around 30% in limited stage disease and
50% in extensive stage disease and also provides a small incre-
ental improvement in the prospect for survival – although that
eneﬁt has recently been called into question [4]. National treat-
ent guidelines [5,6] continue to recommend PCI even though
here have been signiﬁcant advances in the imaging and treatment
f brain metastases [7] since many of the original studies advo-
ating the use of PCI were published. In addition, there is now
 greater awareness of the potential deleterious effects of whole
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brain irradiation on stem cell compartments within the brain, the
presence of which in humans was originally reported in 1998 [8].
This observation encouraged the development of techniques to
limit radiation dose to critical structures such as the hippocampus
[9] and subventricular zone [10]. With the accumulation of more
recent information it seems timely to review the indications for
PCI. In particular the possibility that some of the early random-
ized studies of PCI may  have failed to exclude patients with early
metastatic disease in the brain resulting in exaggerated relapse
rates in untreated controls will be addressed. In the current era of
personalized medicine, a one size ﬁts all approach may  no longer
apply to PCI especially since for most patients with small cell lung
cancer this prescriptive still has more to do with the quality of
remaining life rather than long term survival.
2. Discussion
Studies considered pivotal in supporting the use of PCI (Table 1)
have been identiﬁed in three meta-analyses [1,11,12] and two cur-
rent national guidelines [5,6]. Over time there has been an evolution
in the use of brain imaging in these studies ranging from none to
CT. Current appropriateness criteria® from the American College of
Radiology recommend contiguous thin slice MRI  with newer con-
trast agents with high relaxivity such as gadobenate (MultiHance®)
to ensure that small metastases are not missed [13,14]. Such tech-
niques were unavailable at the time the clinical trials in Table 1
were carried out. We  performed a ﬁxed effects meta-analysis of the
13 trials recording the use of brain imaging, comparing 3 trials in
which only a minority of patients underwent brain imaging versus
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table  1
CNS relapse rates in untreated controls and treated patients categorized according to the extent that brain imaging was  performed at diagnosis or prior to randomization to
exclude early metastatic disease in the brain.
Proportion with brain imaging Modality CNS relapses without PCI Percent CNS relapses with PCI Percent Timing of relapse
Not stated
Slotman(†E) 59/143 41% 24/143 17% Initial and late
Wagner(†E + ‡L) 8/15 53% 3/16 19% Initial and late
*The minority
Gregor(‡L) CT (13%) 65/120 54% 74/194 38% Initial and late
Hansen(†E + ‡L) None if asymptomatic Not stated Not stated
Laplanche(†E + ‡L) None 57/111 51% 44/100 44% Initial and late
Total 122/231 53% Total 118/294 40%
*The majority
Aroney(†E + ‡L) CT 57/139 41% 6/30 20% Initial and late
Arriagada(†E + ‡L) CT 67/149 45% 28/145 19% Initial
Beiler(†E + ‡L) Nuclear medicine 5/31 16% 0/23 0% Initial
Cao(‡L) CT 8/25 32% 1/26 3.8% Initial and late
Eagen(‡L) CT 11/15 73% 2/15 13% Initial and late
Jackson(†E + ‡L) Nuclear medicine 4/15 27% 0/14 0% Initial and late
Maurer(†E + ‡L) CT/nuclear medicine 15/84 18% 3/79 4% Initial and late
Niranen(‡L) Nuclear medicine 7/26 27% 0/25 0% Initial and late
Ohonoshi(†E + ‡L) CT 12/23 52% 5/23 22% Initial and late
Seydell(‡L) CT 22/122 18% 5/107 5% Initial and late
Total 208/629 33% 50/487 10%
* Relapse pooled proportions compared according to imaging (minority versus majority of observed patients) 2 test statistic = 27.86, degrees of freedom = 1, (p < 0.0001),
(minority versus majority of treated patients) 2 test statistic = 96.87, degrees of freedom = 1, (p < 0.0001).
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0 where the majority of patients had brain imaging as part of stag-
ng or follow up prior to randomization to PCI or observation. The
ooled relapse rate in untreated controls was signiﬁcantly higher in
he former group (53% versus 33%, 2 p < 0.0001). The difference was
ven greater between the treated groups, possibly reﬂecting a more
imited effect of low dose PCI radiation prescriptions delivered to
atients who already had subclinical brain metastases (undetected
y the lack of imaging). Notably there was no difference in the two
roups in the proportion of trials including or excluding patients
ith extensive disease (67% versus 60%, Fisher exact probability test
 = 1.0). The impact of switching from CT to MR  imaging in stag-
ng patients with small cell lung cancer at presentation has been
eported to increase the detection rate of brain metastases from
0% to 24% [15]. The utility of contemporary MRI  methodology in
electing patients for PCI in whom no evidence of brain metastases
an be found may  be revealed in pending investigations such as
RG CC003 (which is an NRG Oncology study of hippocampal spar-
ng PCI) that mandates volumetric MR  imaging at the time of patient
egistration.
One of the key justiﬁcations for PCI was the premise that the
reatment of brain metastases from small cell lung cancer was rel-
tively ineffective. In the 1970s palliative whole brain irradiation
as the mainstay of treatment. Since a landmark publication in
987 describing radiosurgery in the treatment of brain metastases
n general [16], radiosurgery has become commonplace. The poten-
ial improvement in local control achievable with fractionation as
s used with extracranial stereotactic body radiation therapy has
et to be exploited [17]. As far as small cell lung cancer is con-
erned, radiosurgery appears to provide excellent local control but
atients remain at signiﬁcant risk from subsequent distant failure
lsewhere in the brain [18], and often in the context of relapsed
xtracranial disease [19]. Alternative schedules of whole brain irra-
iation may  provide superior local control than previously reported
n patients unsuitable for radiosurgery [20]. One of the principal
imitations of the PCI studies is the absence of or limited radio-
ogical surveillance reported in the no PCI arms. The efﬁcacy of
alvage treatment reﬂected the therapeutic options available at
hat time for patients who had relapsed clinically and was generallynot well documented. Nevertheless, the limited data available [21]
from the era of CT imaging have shown that palliative whole brain
irradiation given at the time of asymptomatic relapse may halve the
risk of death with active CNS disease (20%) compared to patients
treated at the time of clinical relapse (38%) and could lead to pro-
longed tumour control and survival. The clinical equipoise still lies
between the merits of careful surveillance and the need to treat
previously undetected brain metastases sooner in a minority of
patients, versus the potential morbidity of (unnecessary) prophy-
lactic whole brain irradiation in those patients who were destined
never to experience an initial intracranial relapse in the ﬁrst place
[21].
There is now a large body of evidence documenting the detri-
mental effects of whole brain irradiation [22]. The relevance of this
information to PCI is tempered by the observation that many stud-
ies describe patients receiving therapeutic doses of whole brain
irradiation rather than the lower prophylactic doses commonly
used in PCI. Nevertheless, the question of radiation dose has been
addressed in dose escalation studies using PCI. Gregor and col-
leagues were the ﬁrst to report improved local control with a higher
dose of radiotherapy. Notably Le Pechoux and colleagues [23], in a
larger collaborative study, were unable to replicate the improve-
ment in local control reported by Gregor using the same modest
increase in total radiation dose from 2500 cGy in 10 daily fractions
to 3600 cGy in 18 daily fractions. It should be noted that the primary
end point in that study was  the incidence of all brain metastases at
2 years. A subset analysis of patients with brain metastases as the
ﬁrst isolated site of failure showed a highly signiﬁcant reduction in
brain metastases as the ﬁrst isolated site of failure in patients in the
high dose arm. In addition Wolfson and colleagues [24], who  par-
ticipated in that collaborative study for the RTOG (protocol 0212),
prospectively performed neurocognitive and quality of life testing
on their patients and found signiﬁcantly greater neurocognitive
decline among patients receiving 3600 cGy including a subset who
received that dose using an accelerated hyperfractionated schedule
(150 cGy b.i.d.). Assuming 80% recovery between fractions and an
alpha/beta ratio of 2, this schedule would be equivalent to a total
dose of ∼4400 cGy in daily fractions of 200 cGy. Further analysis
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Table  2
Relaxivity of gadolinium chelates at 1.5 T.
Gadolinium chelate R1 (L-mmol−1 s−1)
aGadofosveset Ablavar® 19
Gadobenate MultiHance® 6.3–7.9
bGadoxetate Primovist® 6.9
Gadobutrol Gadavist® 4.7–5.2
Gadoteridol Prohance® 4.1
Gadopentetate Magnevist® 3.9–4.1
Gadodiamide Omniscan® 3.3–4.3
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[a FDA approved for angiography only.
b FDA approved for liver imaging only.
howed that chronic neurotoxicity was more likely to be seen in the
lderly when age was introduced as a continuous variable. Addi-
ional potentially confounding observations include reports that
atients with small cell lung cancer are more cognitively impaired
t diagnosis than the general population [25], that patients with
mall cell lung cancer are cognitively impaired following treat-
ent of their extracranial disease before commencing PCI [26,27],
nd that cognitive function in patients with malignant disease in
eneral deteriorates further in the weeks immediately preceding
eath [28]. Current guidelines recommend low dose PCI, typically
500 cGy in 10 daily fractions in order to minimize late sequelae in
ong-term survivors. However conservative radiation prescriptions
ay  not entirely eliminate the chance of radiation injury notably
n subsets of high risk patients such as the elderly [29] and patients
ho have been exposed to cis-platin [30]. Whether or not radia-
ion dose painting which can reduce exposure of structures such
s the hippocampus to radiation results in meaningful beneﬁt to
atients is the subject of on going trials (ClinicalTrials.gov identi-
er: NCT01780675, NCT01797159, NCT02058056).
. Conclusion
So, where does this leave us when having a discussion with
atients regarding the merits of PCI? Firstly we should acknowledge
hat the risk of intracranial relapse has likely been overestimated
n the past and the efﬁcacy of contemporary salvage treatments for
ntracranial relapse may  be underestimated especially if provided
efore patients become symptomatic [21]. Treatment guidelines
ecommend that only patients who have responded to systemic
reatment should be considered for PCI. PCI should be adminis-
ered only after all of the planned induction chemotherapy has
een completed [31]. We  should only be offering PCI to patients in
hom asymptomatic small volume brain metastases have recently
een excluded by volumetric MR  imaging preferably using gadolin-
um chelates with high relaxivity (Table 2). If asymptomatic brain
etastases are discovered they should be managed on their merits
ccording to generally accepted treatment guidelines. We  should
ecord whether there is any pre-existing cognitive or hearing loss,
specially in the elderly. We  should be aware of the possibil-
ty of a patient being non-compliant with close surveillance over
he ﬁrst two years of follow-up which is the time-frame when
lmost all intracranial relapses are expected to occur. Patients
an be MRI  averse due to claustrophobia. They may  have renal
mpairment following chemotherapy and cannot be given gadolin-
um. Are sophisticated salvage treatments available in a timely
anner? When PCI is recommended, should patients be treated
ith hippocampal sparing as a matter of routine in the absence
f level I evidence? And what of the inner ear and subventric-
lar zone? Do these locations deserve radiation dose sparing
oo?
In the authors’ view, one size does not ﬁt all and there remain
any opportunities to research PCI and ﬁnesse the selection
f patients and the delivery of treatment. Ideally the primary
[
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endpoints should be the rate of isolated ﬁrst relapse in the brain
and measures of quality of life in patients in whom the brain is
the ﬁrst site of failure. Patients with extracranial ﬁrst site of failure
or progression become a source of confounding variates reﬂect-
ing the need to offer second line therapies for systemic disease as
well as being the origin of subsequent reseeding of the brain with
new metastases. The use of overall survival as the primary endpoint
should be avoided. The economic cost of incremental surveillance
as well as the psychological impact on patients should be noted.
Nevertheless, any future improvement in the salvage of extracra-
nial relapse could potentially increase rather than reduce the utility
of PCI in controlling occult metastatic disease at presentation in the
brain of patients with a diagnosis of small cell lung cancer [32].
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